SAB Biotherapeutics, Inc. (SABSW)
CIK 1833214 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 91.0M shares as of Aug 3, 2026 (10-Q). Share count fell from 52.3M to 9.2M between Oct 31, 2023 and Mar 18, 2024, a pattern consistent with a reverse split (roughly 1-for-6); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Enrollment Date Warrants | 90.5M | $218.75 | — | — |
| Pre-Funded Warrants | 2.8M | $0.0001 | — | — |
| Preferred PIPE Series B Warrants | 1.5M | not tagged | — | — |
| Private Placement Warrants | 850,119 | not tagged | — | FV $3,000 |
| Preferred Pipe Placement Agent Warrants | 850,119 | $6.3 | — | — |
| Pipe Private Placement Warrants | 736,337 | $10.8 | — | — |
| Pipe Warrants | 736,337 | not tagged | — | — |
| Business Combination Public Warrants | 575,000 | not tagged | — | — |
| Release Date Warrants | 500,000 | $175 | — | — |
| Preferred Tranche C Warrants | 107,115 | not tagged | 5y | — |
| Preferred Tranche B Warrants | 42,846 | not tagged | 0.2y | — |
| Ladenburg Agreement Warrants | 30,000 | $5.424 | 3y | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 2.8M underlying shares, as reported Mar 31, 2026 (10-Q).
Reported exercise price: $0.01 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 93.7M = 91.0M O/S + 2.8M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 6, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Registrations and offerings
Registered offering capacity on live registrations: $1156.3Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 3 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full SABSW workspace